Table 2.
Genes with the greatest fold change in expression from baseline at week 12 in the 200 mg mirikizumab group, adjusted for placebo
| Most decreaseda | Most increaseda |
| REG1B** | ABCG2 ++ |
| MMP3** | HMGCS2 ++ |
| REG3A** | AQP8 ++ |
| DUOXA2** | TMIGD1 ++ |
| SLC6A14** | GUCA2A ++ |
| DMBT1** | SLC26A2 ++ |
| MMP1** | LOC101928405 ++ |
| REG1P** | SLC26A3 + |
| S100A8** | MS4A12 + |
| IL1β** | UGT2A3 + |
| IGKV2D-40** | TRPM6 + |
| PI3** | NXPE4 + |
| TNIP3* | SLC16A9 + |
| REG1A* | ADH1C + |
| IDO1* | PCK1 + |
| DUOX2* | CDKN2B-AS1 + |
| NOS2* | TMEM236 + |
| MMP10* | CD177P1 + |
| CXCL1* | SLC17A4 + |
| PTGS2* | ZG16 + |
a
Genes ordered by greatest to least magnitude of fold change.
*
PBO, placebo; less than PBO by at least 0.5 log2 units-fold; **less than PBO by at least 1 log2 unit-fold; + greater than PBO by at least 0.5 log2 units-fold; ++ greater than PBO by at least 1 log2 unit-fold.